Navigation Links
Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
Date:1/9/2012

VANCOUVER, British Columbia, Jan. 9, 2012 /PRNewswire/ -- Xenon today announced a strategic alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover and develop compounds and companion diagnostics for the potential treatment of pain.

"We are delighted to be collaborating with Genentech," said Simon Pimstone, President and CEO of Xenon. "Genentech is among the world's leading biotech companies and an ideal strategic partner for Xenon as we share a common emphasis on using human genetics for drug development.  Further, this collaboration allows Xenon to both deepen and broaden our pipeline of novel medicines in development."

Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain. Under the terms of the agreement, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products. Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications.  In addition, Xenon will receive royalties on sales of products resulting from the collaboration. 

Michael Hayden, CSO of Xenon added: "This new alliance, which represents our sixth partnership with a major pharmaceutical company to date, once again highlights the keen interest in Xenon's unique genetics approach and in our translational R&D capabilities." 

About Xenon Pharmaceuticals Inc. (Xenon)

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

 


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
2. Xenon Announces Appointment of EVP, Research & Development
3. DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
4. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
5. Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
6. Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System
7. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
8. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
9. Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care
10. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
11. World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Clean Holdings, Inc. (Nasdaq: UCTT), a leading developer ... the semiconductor capital equipment, flat panel, medical, energy ... for the fourth quarter and fiscal year ended ... year of extraordinary growth for UCT. Total revenue ... with continued focus on operational excellence resulted in ...
(Date:2/22/2017)... YORK , Feb. 22, 2017 Summary ... cord partnering deals and agreements entered into by the ... http://www.reportlinker.com/p03605680-summary/view-report.html Description The Global Spinal Cord ... and access to partnering deals and agreements entered into ... Trends in partnering deals - Top deals by ...
(Date:2/22/2017)... 2017 Summary Provides understanding ... agreements entered into by the worlds leading healthcare ... Description The Global Atherosclerosis Partnering Terms ... access to partnering deals and agreements entered into ... - Trends in partnering deals - Top ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the leading ... Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” http://www.beckersspine.com/spine-leaders/item/35348- ... in Michigan performing minimally invasive back surgery that often results in less post-operative ...
(Date:2/22/2017)... ... February 22, 2017 , ... The SeniorCare Investor will ... Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording of the ... of the Interactive Webinar Series. , If you want to find out what really ...
(Date:2/22/2017)... ... , ... BrightStar Care Charleston , a home care and medical staffing ... (MUSC) Center on Aging’s Senior Expo on Thursday, March 23, 2017, at the ... resource in our community. We are thrilled to participate in this event because we ...
(Date:2/22/2017)... ... February 22, 2017 , ... Physicians ... African American/Black students who want to become physicians. PMF also provides a network ... physicians in the Oakland/San Francisco Northern California, Bay Area. PMF’s mission is to ...
Breaking Medicine News(10 mins):